Table 1 Clinical characteristics and FIGO stage distribution of 72 cervical cancer patients with extensive PET-positive pelvic, para-aortic, and/or supraclavicula node disease treated with curative-intent PET-guided extended-field chemo-IMRT/3D-brachytherapy
PET-based staging | N1 (multiple pelvic-only nodes) | M1 (para-aortic and/or supraclavicular nodes without visceral metastasis) | |
|---|---|---|---|
The PET-detected highest level of lymph node involvement | pelvic | para-aortic | supraclavicular |
No. of Patients | 26 | 31 | 15 |
Age at diagnosis, years | |||
Median | 50.9 | 53.1 | 52.5 |
Range | 32.3–73.6 | 29.8–73.8 | 36.9–68.7 |
Tumor histology (%) | |||
Squamous cell carcinoma | 26 (100) | 28 (90.3) | 12 (80.0) |
Adenocarcinoma | 0 (0) | 2 (6.5) | 3 (20) |
Adenosquamous | 0 (0) | 1 (3.2) | 0 (0) |
FIGO clinical stage | |||
IA2-IB2 | 5 (19.2) | 8 (25.8) | 4 (26.7) |
IIA-IIB | 18 (69.2) | 18 (58.1) | 9 (60.0) |
IIIA-IIIB | 3 (11.5) | 3 (9.7) | 1 (6.7) |
IVA | 0 (0) | 2 (6.5) | 1 (6.7) |